PT3130592T - Análogos do composto 4h-pirazolo[1,5-]benzimidazole como inibidores de parp - Google Patents

Análogos do composto 4h-pirazolo[1,5-]benzimidazole como inibidores de parp

Info

Publication number
PT3130592T
PT3130592T PT157774449T PT15777444T PT3130592T PT 3130592 T PT3130592 T PT 3130592T PT 157774449 T PT157774449 T PT 157774449T PT 15777444 T PT15777444 T PT 15777444T PT 3130592 T PT3130592 T PT 3130592T
Authority
PT
Portugal
Prior art keywords
pyrazolo
analogues
parp inhibitors
benzimidazole compound
benzimidazole
Prior art date
Application number
PT157774449T
Other languages
English (en)
Inventor
Ding Zhaozhong
Chen Shuhui
Li Gang
Wang Cailin
Zhang Zhibo
Tu Ronghua
Yue Yang
Chen Hailiang
Sun Wenjie
Huang Lu
Original Assignee
Hubei Bio Pharmaceutical Industrial Tech Institute Inc
Humanwell Healthcare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410144173.0A external-priority patent/CN104974161B/zh
Application filed by Hubei Bio Pharmaceutical Industrial Tech Institute Inc, Humanwell Healthcare Group Co Ltd filed Critical Hubei Bio Pharmaceutical Industrial Tech Institute Inc
Publication of PT3130592T publication Critical patent/PT3130592T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
PT157774449T 2014-04-10 2015-03-30 Análogos do composto 4h-pirazolo[1,5-]benzimidazole como inibidores de parp PT3130592T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410144173.0A CN104974161B (zh) 2014-04-10 2014-04-10 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
CN201510113090 2015-03-13

Publications (1)

Publication Number Publication Date
PT3130592T true PT3130592T (pt) 2019-11-21

Family

ID=54287319

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157774449T PT3130592T (pt) 2014-04-10 2015-03-30 Análogos do composto 4h-pirazolo[1,5-]benzimidazole como inibidores de parp

Country Status (22)

Country Link
US (1) US9856262B2 (pt)
EP (1) EP3130592B1 (pt)
JP (1) JP6359175B2 (pt)
KR (1) KR101921486B1 (pt)
CN (1) CN106459057B (pt)
AU (1) AU2015245786B2 (pt)
BR (1) BR112016023397B1 (pt)
CA (1) CA2944801C (pt)
DK (1) DK3130592T3 (pt)
ES (1) ES2754590T3 (pt)
HU (1) HUE047410T2 (pt)
IL (1) IL248258B (pt)
MX (1) MX368496B (pt)
NZ (1) NZ725165A (pt)
PL (1) PL3130592T3 (pt)
PT (1) PT3130592T (pt)
RU (1) RU2672722C2 (pt)
SA (1) SA516380051B1 (pt)
SG (1) SG11201608438YA (pt)
TW (1) TWI671301B (pt)
WO (1) WO2015154630A1 (pt)
ZA (1) ZA201607736B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974161B (zh) * 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
US10428073B2 (en) * 2015-09-30 2019-10-01 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
JP7261747B2 (ja) 2017-04-27 2023-04-20 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規二環式ピラゾール誘導体
CN115028641A (zh) * 2022-07-19 2022-09-09 湖南大学 一种钴催化合成5,8-双官能团取代咪唑并[1,2-a]吡嗪类化合物的方法
CN116969954B (zh) * 2023-09-21 2023-11-28 广东省农业科学院农业质量标准与监测技术研究所 一类含内酰胺的三环稠合杂环化合物及其应用
CN117534677B (zh) * 2024-01-09 2024-03-12 广东省农业科学院农业质量标准与监测技术研究所 一类含亚胺的三环稠合杂环化合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916051A (en) * 1987-04-07 1990-04-10 Konica Corporation Silver halide color photographic light-sensitive material
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
EP1973909A2 (en) * 2005-12-22 2008-10-01 Biogen Idec MA Inc. Transforming growth factor modulators
WO2007144669A1 (en) 2006-06-15 2007-12-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp)
ES2559679T3 (es) * 2006-06-20 2016-02-15 Abbvie Inc. Pirazoloquinazolinonas como inhibidores de PARP
GB0701273D0 (en) 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
ES2535511T3 (es) 2012-04-26 2015-05-12 Helmut Schickaneder Ésteres de bendamustina y compuestos relacionados, y uso médico de los mismos
ES2587939T3 (es) 2012-05-04 2016-10-27 Merck Patent Gmbh Derivados de pirrolotriazinona
EP2666775A1 (en) * 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
RU2014151004A (ru) 2012-06-07 2016-08-10 Ф. Хоффманн-Ля Рош Аг Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
EP2870140B8 (en) 2012-07-09 2016-09-28 Lupin Limited Tetrahydroquinazolinone derivatives as parp inhibitors
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
DK2882714T3 (da) * 2012-08-08 2020-01-20 Merck Patent Gmbh (aza-)isoquinolinonderivater
CN104974161B (zh) 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物

Also Published As

Publication number Publication date
BR112016023397A2 (pt) 2017-08-15
IL248258B (en) 2018-11-29
RU2016144202A3 (pt) 2018-05-15
RU2016144202A (ru) 2018-05-15
ZA201607736B (en) 2017-09-27
NZ725165A (en) 2018-04-27
CN106459057A (zh) 2017-02-22
EP3130592A1 (en) 2017-02-15
PL3130592T3 (pl) 2020-05-18
MX368496B (es) 2019-10-04
CN106459057B (zh) 2019-06-07
US9856262B2 (en) 2018-01-02
US20170029430A1 (en) 2017-02-02
TWI671301B (zh) 2019-09-11
WO2015154630A1 (zh) 2015-10-15
EP3130592B1 (en) 2019-08-14
SA516380051B1 (ar) 2020-05-17
ES2754590T3 (es) 2020-04-20
TW201620913A (zh) 2016-06-16
SG11201608438YA (en) 2016-11-29
JP2017510653A (ja) 2017-04-13
DK3130592T3 (da) 2019-11-04
KR101921486B1 (ko) 2018-11-26
BR112016023397B1 (pt) 2022-08-16
KR20170005807A (ko) 2017-01-16
AU2015245786B2 (en) 2018-03-15
RU2672722C2 (ru) 2018-11-19
AU2015245786A1 (en) 2016-11-03
HUE047410T2 (hu) 2020-04-28
EP3130592A4 (en) 2017-09-06
JP6359175B2 (ja) 2018-07-18
MX2016013265A (es) 2017-05-03
CA2944801C (en) 2019-02-12
CA2944801A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
IL287517A (en) Benzimidazole compounds as c-kit inhibitors
IL259560A (en) Inhibitors of the menin-mll interaction
HRP20181772T1 (hr) Spoj za obradu gnojiva koje sadrži ureu
HK1251876A1 (zh) 作為atx抑制劑的二環化合物
HK1246787A1 (zh) 作為atx抑制劑的二環化合物
IL254318B (en) History of benzaimidazoles as bromodomain inhibitors
IL251932A0 (en) Benzylpropargyl ether as nitrification inhibitors
ZA201808345B (en) Capsules comprising benzylpropargylethers for use as nitrification inhibitors
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
HUE047410T2 (hu) 4H-Pirazolo[1,5-a]benzimidazol vegyület analógjai, mint PARP inhibitorok
IL266745B (en) Benzodiazolonium compounds as enac inhibitors
HK1246184A1 (zh) 作為a7-烟碱乙酰膽碱受體激動劑的氨基苯並惡唑化合物
ZA201700518B (en) Use of active compound compositions
ZA201607256B (en) Active compound combinations
GB201520189D0 (en) Compound for use
GB201508787D0 (en) Pharmaceutically active compounds
TWM489712U (en) Structure of nailing machine
GB201403538D0 (en) Pharmacologically active compounds